Boston Scientific Corporation
BSX
$105.87
-$0.52-0.49%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 37.09% | 14.60% | 16.38% | 46.01% | 100.44% |
| Total Depreciation and Amortization | 7.08% | 6.17% | 6.10% | 4.84% | 5.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -44.94% | 85.36% | 59.92% | 129.97% | 36.14% |
| Change in Net Operating Assets | 103.80% | 59.90% | 40.00% | -122.43% | -133.73% |
| Cash from Operations | 62.80% | 53.90% | 37.24% | 24.78% | 23.86% |
| Capital Expenditure | -1.14% | -2.44% | -11.11% | -18.90% | -28.41% |
| Sale of Property, Plant, and Equipment | 100.00% | 100.00% | -50.00% | -100.00% | -83.33% |
| Cash Acquisitions | -552.36% | -225.83% | -156.21% | -97.94% | 18.46% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.69% | -140.35% | -362.50% | -487.80% | -236.84% |
| Cash from Investing | -274.14% | -148.51% | -120.94% | -78.17% | -4.27% |
| Total Debt Issued | -16.08% | -17.53% | -- | -- | 1,901.71% |
| Total Debt Repaid | -204.88% | -145.97% | -13,125.00% | -13,125.00% | -53,200.00% |
| Issuance of Common Stock | 36.87% | 33.17% | 26.37% | 19.02% | 17.86% |
| Repurchase of Common Stock | -55.36% | -55.36% | -55.36% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 100.00% | 100.00% |
| Other Financing Activities | -130.11% | -61.22% | -75.28% | -25.68% | 57.53% |
| Cash from Financing | -92.98% | -70.91% | 36,180.00% | 18,044.44% | 825.00% |
| Foreign Exchange rate Adjustments | 522.22% | 418.18% | -175.00% | 140.00% | -50.00% |
| Miscellaneous Cash Flow Adjustments | -150.00% | -- | -- | 0.00% | 300.00% |
| Net Change in Cash | -195.01% | -190.95% | -541.43% | 138.68% | 1,408.02% |